Ascentage Pharma Group International, a clinical-stage biotechnology company, engages in developing therapies for cancers, hepatitis B virus (HBV), and age-related diseases in the United States and Mainland China. More Details
+ 1 more risk
Mediocre balance sheet and slightly overvalued.
Share Price & News
How has Ascentage Pharma Group International's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 6855 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: 6855's weekly volatility (9%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: 6855 underperformed the Hong Kong Biotechs industry which returned 45.4% over the past year.
Return vs Market: 6855 underperformed the Hong Kong Market which returned 22.4% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Ascentage Pharma Group International's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StWhat Kind Of Shareholders Hold The Majority In Ascentage Pharma Group International's (HKG:6855) Shares?
3 months ago | Simply Wall StThe Ascentage Pharma Group International (HKG:6855) Share Price Has Gained 37% And Shareholders Are Hoping For More
Is Ascentage Pharma Group International undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 6855 (HK$41.6) is trading below our estimate of fair value (HK$62.07)
Significantly Below Fair Value: 6855 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 6855 is unprofitable, so we can't compare its PE Ratio to the Hong Kong Biotechs industry average.
PE vs Market: 6855 is unprofitable, so we can't compare its PE Ratio to the Hong Kong market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 6855's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 6855 is overvalued based on its PB Ratio (8.9x) compared to the HK Biotechs industry average (4.2x).
How is Ascentage Pharma Group International forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 6855 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 6855 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 6855 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 6855's revenue (54.9% per year) is forecast to grow faster than the Hong Kong market (12.7% per year).
High Growth Revenue: 6855's revenue (54.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 6855 is forecast to be unprofitable in 3 years.
How has Ascentage Pharma Group International performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 6855 is currently unprofitable.
Growing Profit Margin: 6855 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 6855 is unprofitable, and losses have increased over the past 5 years at a rate of 36.3% per year.
Accelerating Growth: Unable to compare 6855's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6855 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (43.1%).
Return on Equity
High ROE: 6855 has a negative Return on Equity (-80.04%), as it is currently unprofitable.
How is Ascentage Pharma Group International's financial position?
Financial Position Analysis
Short Term Liabilities: 6855's short term assets (CN¥1.1B) exceed its short term liabilities (CN¥276.1M).
Long Term Liabilities: 6855's short term assets (CN¥1.1B) exceed its long term liabilities (CN¥608.3M).
Debt to Equity History and Analysis
Debt Level: 6855's debt to equity ratio (61.2%) is considered high.
Reducing Debt: Insufficient data to determine if 6855's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 6855 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 6855 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 46.4% each year
What is Ascentage Pharma Group International current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 6855's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 6855's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 6855's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 6855's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 6855's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dajun Yang (57 yo)
Dr. Dajun Yang Co-Founded Ascentage Pharma Group International in May 2019 and serves as its Chairman and has been its Director since November 17, 2017 and serves as its CEO since July 2018. His Roles an...
Experienced Management: 6855's management team is considered experienced (2.3 years average tenure).
Experienced Board: 6855's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: 6855 insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 21.6%.
Ascentage Pharma Group International's company bio, employee growth, exchange listings and data sources
- Name: Ascentage Pharma Group International
- Ticker: 6855
- Exchange: SEHK
- Founded: 2009
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: HK$10.300b
- Shares outstanding: 247.60m
- Website: https://www.ascentagepharma.com
Number of Employees
- Ascentage Pharma Group International
- Building B7
- 7th Floor
- Jiangsu Province
Ascentage Pharma Group International, a clinical-stage biotechnology company, engages in developing therapies for cancers, hepatitis B virus (HBV), and age-related diseases in the United States and Mainlan...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/06/18 10:23|
|End of Day Share Price||2021/06/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.